VX
Vertex Pharmaceuticals Incorporated Common Stock (VX1)
XETR
455.65
+8.50 (+1.90%)
Real-time Data
07:00 AM
Day's Range
448.55455.65
52 wk Range
345.00480.40
Financial Statements - VX1 - Vertex Pharmaceuticals Incorporated Common Stock
Revenue
12.00B▲ 29.6%
Net Income
3.95B▲ 978.3%Net Margin 32.9%
EBITDA
5.24B▲ 1185.4%
Free Cash Flow
3.19B▲ 488.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 12B | 9.26B | 9.86B | 8.93B | 7.57B | 6.20B |
| Cost of Goods | 1.65B | 1.28B | 1.26B | 1.08B | 904.20M | 736.30M |
| Gross Profit | 10.35B | 7.97B | 8.60B | 7.85B | 6.67B | 5.46B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 4.55B | -196.13M | 4.30B | 4.36B | 3.89B | 2.86B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -388.80M | -71.93M | -498.30M | -222.80M | -1.10B | 283.50M |
| Pre Tax Income | 4.64B | 208.82M | 4.37B | 4.23B | 2.73B | 3.11B |
| Income Tax | 690M | 658.90M | 760.20M | 910.40M | 388.30M | 405.20M |
| Net Income | 3.95B | -450.08M | 3.61B | 3.32B | 2.34B | 2.71B |
| EPS Basic | 15.46 | -2.08 | 14.05 | 12.97 | 9.09 | 10.44 |
| EPS Diluted | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 |
| Basic Shares Outstanding | 255.70M | 216.72M | 268.81M | 262.96M | 264.60M | 266.80M |
| Diluted Shares Outstanding | 255.70M | 216.72M | 268.81M | 262.96M | 264.60M | 266.80M |
| Ebit | 4.65B | 234.53M | 4.42B | 4.28B | 2.79B | 3.17B |
| Ebitda | 5.24B | 408.23M | 5.08B | 4.49B | 4.02B | 3.29B |
| Net Income Continuous Operations | 3.95B | -450.08M | 3.61B | 3.32B | 2.34B | 2.71B |
| Minority Interests | - | - | - | - | - | 0 |
| Preferred Stock Dividends | - | - | - | - | - | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
